Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024
Revolution Medicines, Inc. (RVMD) will report financial results for Q4 and full year 2023 on Feb 26, 2024. The company is a clinical-stage oncology firm focusing on RAS-addicted cancers. A webcast by senior management will discuss financial results and corporate progress.
02/20/2024 - 04:05 PM
REDWOOD CITY, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the fourth quarter and full year 2023 on Monday, February 26, 2024, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), Revolution Medicines’ senior management team will host a webcast to discuss the financial results for the quarter and full year, and provide an update on corporate progress.
To listen to the live webcast, or access the archived webcast, please visit: https://ir.revmed.com/events-and-presentations . Following the live webcast, a replay will be available on the company’s website for at least 14 days.
About Revolution Medicines, Inc.
Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS companion inhibitors for use in combination treatment strategies. The company’s RAS(ON) inhibitors RMC-6236, a RAS(ON) multi-selective inhibitor, RMC-6291, a RAS(ON) G12C-selective inhibitor, and RMC-9805, a RAS(ON) G12D-selective inhibitor, are currently in clinical development. Additional RAS(ON) mutant-selective inhibitors in the company’s development pipeline include RMC-5127 (G12V), RMC-0708 (Q61H) and RMC-8839 (G13C).
When will Revolution Medicines (RVMD) report financial results for Q4 and full year 2023?
Revolution Medicines will report financial results on Feb 26, 2024, after market close.
What type of company is Revolution Medicines (RVMD)?
Revolution Medicines is a clinical-stage oncology company focusing on developing novel targeted therapies for RAS-addicted cancers.
When will the webcast by Revolution Medicines' senior management team take place?
The webcast will occur on Feb 26, 2024, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).
Where can one access the live webcast by Revolution Medicines (RVMD)?
To listen to the live webcast, visit https://ir.revmed.com/events-and-presentations.
For how long will the replay of the webcast be available on Revolution Medicines' website?
The replay will be accessible on the company's website for at least 14 days following the live webcast.
RVMD Rankings
#2552 Ranked by Stock Gains
RVMD Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Other, Manufacturing, Biological Product (except Diagnostic) Manufacturing
Country
US
City
Redwood City
About RVMD
revolution medicines discovers and develops new drugs that harness the therapeutic potential of frontier oncology targets on behalf of cancer patients. our innovative product engine draws inspiration from nature and evolution, which offer insights into cancer targets, disease mechanisms and therapeutic approaches. we pay particular attention to natural products that are inherently rich with biological function as a result of natural selection and can inform and guide our discovery and development of small molecules that can modulate these targets.
